These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33881797)

  • 1. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
    Blonde L; Bailey T; Sullivan SD; Freemantle N
    Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
    Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
    Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
    Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
    Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
    Meneghini L; Blonde L; Gill J; Dauchy A; Bacevicius A; Strong J; Bailey TS
    Diabetes Obes Metab; 2020 Nov; 22(11):1995-2003. PubMed ID: 32538550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
    Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
    Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
    Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
    Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
    Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
    Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
    Bailey TS; Wu J; Zhou FL; Gupta RA; Menon AA; Berhanu P; Westerbacka J; Van Vleet J; Blonde L
    Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
    Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
    Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
    Cheng A; Harris S; Giorgino F; Seufert J; Ritzel R; Khunti K; Lauand F; Melas-Melt L; Westerbacka J; Bosnyak Z; Rosenstock J
    Diabetes Obes Metab; 2020 Mar; 22(3):346-354. PubMed ID: 31646724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
    Bolli GB; Cheng A; Charbonnel B; Aroda VR; Westerbacka J; Bosnyak Z; Boëlle-Le Corfec E; Rosenstock J
    Diabetes Obes Metab; 2021 Jul; 23(7):1588-1593. PubMed ID: 33687748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
    Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
    Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.
    Seufert J; Wiesli P; Fritsche A; Anderten H; Pegelow K; Pscherer S; Pfohl M
    Diabetes Obes Metab; 2022 Jan; 24(1):72-81. PubMed ID: 34514696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.